New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
07:04 EDTEBSEmergent announces waiting period expiration for Cangene acquisition
Emergent BioSolutions announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with Emergentís proposed acquisition of Cangene has expired. The expiration of the waiting period for antitrust review of the proposed acquisition satisfies one of the conditions to the closing of the acquisition. As announced on December 11, 2013, Emergent and Cangene have entered into a definitive agreement under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222M. Completion of the acquisition is subject to approval by 66 2/3% of the votes cast by Cangene shareholders at a special shareholder meeting scheduled for February 12, approval by the Ontario Superior Court of Justice at a hearing scheduled for February 18 and other customary closing conditions. The transaction is expected to close before the end of1Q14.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
14:49 EDTEBSEmergent BioSolutions files automatic mixed securities shelf
Subscribe for More Information
May 19, 2015
07:06 EDTEBSEmergent BioSolutions signs manufacturing agreement with Prometic Life Sciences
Subscribe for More Information
May 13, 2015
07:07 EDTEBSSoligenix signs development agreement with Emergent BioSolutions
Subscribe for More Information
07:07 EDTEBSGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use